CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0597 (clinicaltrials.gov NCT No: NCT01067469)
Title:Randomized Phase II Trial of Standard Dose Bevacizumab Versus Low Dose Bevacizumab plus Lomustine (CCNU) In Adults with Recurrent Glioblastoma Multiforme
Principal Investigator:John DeGroot
Treatment Agent:Avastin; CCNU
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of
bevacizumab and lomustine can help to control glioblastoma. The safety of this
combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Brain; CNS
Phase of Study:Phase II
Treatment Agents:Avastin
CCNU
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Every 2 weeks for arm 1 and every 3 weeks for arm 2
Home Care:Patients will take lomustine at home


Hide details for Study Contact InformationStudy Contact Information

Physician Name:John DeGroot
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults